logo
New blood pressure guidelines recommend skipping alcohol and an earlier start to treatment

New blood pressure guidelines recommend skipping alcohol and an earlier start to treatment

CNN21 hours ago
The next time you get your blood pressure checked, expect your medical provider to be a bit more aggressive about high levels. And if you like a glass of wine with dinner or a cocktail on the weekends, brace yourself: New guidelines from the American Heart Association and the American College of Cardiology released Thursday suggest you abstain.
Committees from the heart organizations continuously assess the latest research so they can help medical providers figure out the best approach to high blood pressure, but this is the first new set of guidelines since 2017. Heart disease has long been the No. 1 killer in the world and blood pressure is one of the most easily modifiable ways to avoid such a death. Keeping your blood pressure in check can also reduce your risk of kidney disease, type 2 diabetes and dementia.
Nearly half of all adults in the US have higher than normal blood pressure. The goal numbers for adults haven't changed, according to the guidelines: Normal blood pressure is less than 120/80 mm Hg, elevated blood pressure is 120-129/80 mm Hg. If you are at 130/80 mmHg or higher, according to the new guidelines, your medical provider will want you to make some changes.
Blood pressure is measured in millimeters of mercury, which is abbreviated as mm Hg. The measurement has an upper number, or systolic reading, and a lower number, a diastolic reading: Systolic pressure measures the force of blood as it pumps out of the heart into the arteries, and diastolic is the pressure created as the heart rests between beats.
High blood pressure doesn't have any symptoms typically. But when your blood pressure is high, the force of your blood pushes against the walls of your blood vessels, making your heart less efficient, so both the vessels and heart must work harder. Without treatment, high blood pressure will eventually damage your arteries, raising your risk of having a heart attack or stroke.
The new blood pressure guidelines say that if your systolic blood pressure is in the 130 to 139 range, your medical provider should first encourage you to adopt healthy lifestyle changes. After three to six months, if the lifestyle changes alone don't lower your blood pressure to the goal range, then medication is recommended, the new guidelines say. That's a shift from 2017 recommendation that anyone with systolic blood pressure above 140 should be prescribed lifestyle changes and medication.
'So just trying to more aggressively control blood pressure, for it to be better for more people, to prevent cardiovascular disease, strokes, kidney disease, and now we know lowering blood pressure actually helps reduce the risk for dementia as well. So that's really big news out of this guideline,' said Dr. Daniel Jones, American Heart Association chair of the writing committee for the guidelines.
Lifestyle changes, according to the new guidelines, include maintaining or achieving a healthy weight, eating a heart-healthy diet, reducing the amount of salt in what you eat and drink, managing stress, at least 150 minutes of moderate physical activity per week and resistance exercise like weight training.
There's another shift from 2017: The new guidelines also recommend forgoing alcohol.
The guidelines used to say that if people chose to drink, it should be one drink or less a day for women, and two or less a day for men. Jones said there's just too much evidence now that alcohol negatively impacts your blood pressure.
'A lot of people enjoy drinking, but because the evidence is there, we want you to make an informed decision,' said Jones, who is also dean and professor emeritus of the University of Mississippi School of Medicine. 'There's a lot of individual variability with the relationship between alcohol and blood pressure, but we put forward the ideal as abstinence, and for those who choose to drink, less than one for women and less than two for men.'
Based on a growing body of evidence, there's also more emphasis on how important it is to lower blood pressure to reduce the risk of developing dementia, Jones said.
With more studies about women having trouble with high blood pressure during pregnancy, Jones said, the guidelines also newly emphasize how important it is for people who want to become pregnant or those who are pregnant to monitor their blood pressure. High blood pressure can hurt the pregnancy and can raise a person's risk of having elevated blood pressure even long after pregnancy.
Dietary recommendations still include the DASH diet which is a diet high on fruits, vegetables, whole grains, fish, poultry, beans, nuts, and vegetable oils and and low on fat, sugar, and tropical oils like coconut and palm oils.
'We also harp on sodium again and we know salt and alcohol are favorites for lots of people, but we do recommend limiting salt intake, increasing potassium intake,' Jones said. One easy way to do that is if cooking at home to use potassium-enriched salt substitutes. Sodium intake should be less than 2,300 mg per day, moving toward a more ideal limit of 1,500 mg per day.
For people with overweight or obesity, the guidelines recommend losing at least 5% of body weight. For people with more severe obesity, the guidelines recommend what Jones says are clinically proven interventions: diet and exercise, and weight loss medications including GLP-1s. For people with very severe obesity, the guidelines also suggest surgery.
Jones said he knows it can be difficult for people to keep their blood pressure in check, but taking these steps can help a person's health significantly.
'The reality is the first line of things we recommend for both prevention and treatment of high blood pressure have to do with eating and we live in a very difficult environment for food. It's hard for people to have a low sodium intake. It's hard for people to eat enough potassium. It's hard for people to take in a small number of calories, but the good news is that all that stuff works if you're willing to do it,' Jones said. 'It's hard, but it works.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

Yahoo

time17 minutes ago

  • Yahoo

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets

UnitedHealth stock pops on Buffett's Berkshire share purchase
UnitedHealth stock pops on Buffett's Berkshire share purchase

Yahoo

time17 minutes ago

  • Yahoo

UnitedHealth stock pops on Buffett's Berkshire share purchase

UnitedHealth Group's (UNH) stock jumped early Friday after Warren Buffett's Berkshire Hathaway (BRK-A, BRK-B) revealed Thursday it purchased 5 million shares last quarter. The insurance giant has suffered multiple setbacks in the past couple of years — with earnings misses piling on top of all that, the stock has been under constant pressure, and is down more than 45% year-to-date. But on the news of Berkshire's share purchase, the stock popped nearly 10% in early trading Friday. The last time Berkshire held a stake in the company was when Stephen Hemsley was CEO, between 2006 and 2017. Hemlsey has returned to the role after former CEO Andrew Witty stepped down in May — after a year of compounding headwinds. Last year, the company suffered one of the biggest cyberattacks in history on one of it's subsidiaries, Change Healthcare, which manages payments — creating havoc for health providers for months. The US Health and Human Services Department (HHS) had to step in and assist to help get payments flowing again. The company subsequently announced a larger-than-expected impact from the attack in mid-2024, dragging down major indices. At the end of the year, during the annual shareholder's meeting in New York City, insurance CEO Brian Thompson was shot to death. The struggles for the company didn't end there, as public backlash against the industry swelled in the aftermath, and the entire insurance industry was forced to address the issue of denied claims. In April this year, the company's stock crashed after an earnings miss shocked the Street. In May, Hemsley took over, and in the latest earnings call addressed the missteps the company has made, as well as the higher cost environment that it did not adjust in time to. "Beyond the environmental factors that are affecting the entire sector and more specifically to us, we have made pricing and operational mistakes as well as others," he said on the call. UnitedHealth's stock pop also helped boost the Dow (DJI), which was up about a half percent in early trading. Previously, UnitedHealth's losses dragged the Dow. In May, UnitedHealth was attributed with 88% of the Dow's decline year-to-date. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Buffett Just Bought the Dip--Is This Health Giant the Comeback Play of the Year?
Buffett Just Bought the Dip--Is This Health Giant the Comeback Play of the Year?

Yahoo

time17 minutes ago

  • Yahoo

Buffett Just Bought the Dip--Is This Health Giant the Comeback Play of the Year?

UnitedHealth Group (NYSE:UNH) just caught a lifelinestraight from two of Wall Street's most respected investors. Shares jumped 8.75% at 9.31am today, marking the stock's biggest intraday gain since 2020. The catalyst? Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway disclosed a fresh 5 million-share stake, while David Tepper (Trades, Portfolio)'s Appaloosa Management added another 2.3 million shares. That's a bold vote of confidence for a company that's been hammered this year, down 46% amid regulatory heat and earnings disappointments. Warning! GuruFocus has detected 5 Warning Sign with UNH. The health insurance heavyweight is navigating one of the roughest stretches in its history. A top executive was murdered late last year. In April, the company slashed its full-year outlook, then replaced its CEO with former chief Stephen Hemsley. Most recently, UnitedHealth issued a fresh profit forecast that came in below every single analyst estimatea stunning reversal for a business that had beaten expectations for over 60 straight quarters. So what broke the streak? UnitedHealth underestimated how quickly Americans would return to using medical servicesand set premiums too low as a result. Meanwhile, changes in government-subsidized coverage and payment models are eating into margins. If this trend holds, 2025 could mark the first annual adjusted EPS decline in nearly 20 years. Still, Buffett and Tepper stepping in suggests they see something others don't: a dominant business under temporary pressure, with long-term upside hiding in the wreckage. This article first appeared on GuruFocus.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store